Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Drops By 90.6%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 2,565 shares, a drop of 90.6% from the December 31st total of 27,309 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 6,364 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 6,364 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the company’s shares are sold short.

Invesco Biotechnology & Genome ETF Price Performance

PBE stock traded up $0.12 during midday trading on Thursday, reaching $82.48. 10,561 shares of the company’s stock traded hands, compared to its average volume of 8,398. Invesco Biotechnology & Genome ETF has a fifty-two week low of $54.52 and a fifty-two week high of $85.73. The business has a 50-day moving average price of $82.28 and a two-hundred day moving average price of $74.48. The company has a market capitalization of $264.76 million, a P/E ratio of 20.44 and a beta of 0.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Gerber Kawasaki Wealth & Investment Management grew its position in shares of Invesco Biotechnology & Genome ETF by 4.2% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock worth $16,292,000 after acquiring an additional 10,213 shares in the last quarter. United Capital Financial Advisors LLC bought a new position in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter valued at about $5,946,000. Royal Bank of Canada grew its position in Invesco Biotechnology & Genome ETF by 22.3% in the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after buying an additional 13,767 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Invesco Biotechnology & Genome ETF by 2.5% in the 3rd quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock worth $4,186,000 after acquiring an additional 1,453 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Invesco Biotechnology & Genome ETF by 5.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock worth $2,389,000 after buying an additional 2,103 shares during the period.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.